Register or Sign in to Save this opportunity, or Send an Inquiry.
Cancer Cell-Specific Hyperthermic Chemotherapy Treatment for Surgery-Resistant Abdominal Cancers (Ref # WFU 07-07)
Wake Forest Innovations United States flag United States
Abstract ID:
This treatment uses nanoparticle technology to deliver hyperthermic chemotherapy to patients with metastatic abdominal cancer. This enables intraperitoneal chemotherapy to be delivered using lower doses with higher efficacy, thus limiting toxicity.
Send an Inquiry
Value Proposition

Cancers of the abdomen, such as stomach, colorectal, or ovarian cancer, are difficult to treat effectively due to their tendency to metastasize. The current state-of-the-art treatment, intraperitoneal hyperthermic chemotherapy (IPHC), is effective against tumor cells but also causes undesirable side effects in healthy cells. By incorporating nanoparticle-based compositions into the treatment plan, researchers maximize IPHC efficacy while minimizing side effects due to drug interaction with healthy cells.

Invention Summary

Researchers at Wake Forest University have developed novel nanoparticle-based compositions that can be used to maximize the effectiveness of IPHC while reducing the toxicity of the chemotherapeutic agent to healthy cells. To maximize effectiveness, anti-cancer drugs are heated and then circulated through the peritoneum. Methods of using this composition have been shown experimentally in vitro to reduce the therapy time by over 200 fold (from 2 hours to a mere 30 seconds).

Competitive Benefits

Type of Business Relationship Sought
Exclusive Licensing Arrangement
Possibility of a parallel Sponsored Research Agreement
Last Updated Feb 2014
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL


Opportunity Contact